Publication:
Targeted therapy for immune mediated skin diseases. What should a dermatologist know?

Simple item page
dc.contributor.authorLópez, Edinson
dc.contributor.authorCabrera, Raúl
dc.contributor.authorLecaros, Cristóbal
dc.date.accessioned2024-12-16T15:27:17Z
dc.date.available2024-12-16T15:27:17Z
dc.date.issued2024
dc.description.abstractBackground: Molecularly targeted therapies, such as monoclonal antibodies (mAbs) and Janus Kinase inhibitors (JAKis), have emerged as essential tools in the treatment of dermatological diseases. These therapies modulate the immune system through specific signaling pathways, providing effective alternatives to traditional systemic immunosuppressive agents. This review aims to provide an updated summary of targeted immune therapies for inflammatory skin diseases, considering their pathophysiology, efficacy, dosage, and safety profiles. Methods: The review followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. A systematic search was conducted on PubMed over the past 10 years, focusing on randomized clinical trials, case reports, and case series related to targeted immune therapies in dermatology. Eligibility criteria were applied, and data were extracted from each study, including citation data, study design, and results. Results: We identified 1360 non-duplicate articles with the initial search strategy. Title and abstract review excluded 1150, while a full-text review excluded an additional 50 articles. The review included 143 studies published between 2012 and 2022, highlighting 39 drugs currently under investigation or in use for managing inflammatory skin diseases. Study limitations: The heterogeneity of summarized information limits this review. Some recommendations originated from data from clinical trials, while others relied on retrospective analyses and small case series. Recommendations will likely be updated as new results emerge. Conclusion: Targeted therapies have revolutionized the treatment of chronic skin diseases, offering new options for patients unresponsive to standard treatments. Paradoxical reactions are rarely observed. Further studies are needed to fully understand the mechanisms and nature of these therapies. Overall, targeted immune therapies in dermatology represent a promising development, significantly improving the quality of life for patients with chronic inflammatory skin diseases.
dc.description.versionVersión Aceptada
dc.identifier.citationLópez E, Cabrera R, Lecaros C. Targeted therapy for immune mediated skin diseases. What should a dermatologist know? An Bras Dermatol. 2024 Jul-Aug;99(4):546-567. doi: 10.1016/j.abd.2023.10.002.
dc.identifier.doihttps://doi.org/10.1016/j.abd.2023.10.002
dc.identifier.urihttps://hdl.handle.net/11447/9478
dc.language.isoen
dc.subjectAtopic dermatitis
dc.subjectBiologics
dc.subjectImmune modulators
dc.subjectInflammatory skin diseases
dc.subjectJak inhibitors
dc.subjectPsoriasis
dc.subjectTargeted therapy
dc.titleTargeted therapy for immune mediated skin diseases. What should a dermatologist know?
dc.typeArticle
dcterms.accessRightsAcceso Abierto
dcterms.sourceAnais brasileiros de dermatologia
dspace.entity.typePublication
relation.isAuthorOfPublication00e7d56a-4549-41d5-8c78-f5df4cd223a2
relation.isAuthorOfPublication.latestForDiscovery00e7d56a-4549-41d5-8c78-f5df4cd223a2

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Targeted therapy for immune mediated skin diseases. What should a dermatologist know_.pdf
Size:
2.27 MB
Format:
Adobe Portable Document Format
Description:
Texto Completo
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
347 B
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services